相似文献
1
To be or not to be--an incretin or enterogastrone?
Gut. 2006 Feb;55(2):148-50. doi: 10.1136/gut.2005.071787.
2
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
Gut. 2006 Feb;55(2):243-51. doi: 10.1136/gut.2004.059741. Epub 2005 Jun 28.
3
Gastric emptying and release of incretin hormones after glucose ingestion in humans.
J Clin Invest. 1996 Jan 1;97(1):92-103. doi: 10.1172/JCI118411.
4
Is glucagon-like peptide 1 an incretin hormone?
Diabetologia. 1999 Mar;42(3):373-9. doi: 10.1007/s001250051165.
5
The gastrointestinal tract and glucose tolerance.
Curr Opin Clin Nutr Metab Care. 2004 Jul;7(4):479-84. doi: 10.1097/01.mco.0000134375.01310.97.
6
Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion.
Scand J Gastroenterol. 2011 Apr;46(4):428-35. doi: 10.3109/00365521.2010.537680. Epub 2010 Nov 30.
7
The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
Diabetes Obes Metab. 2014 Jan;16(1):9-21. doi: 10.1111/dom.12119. Epub 2013 May 26.
8
Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility.
Vitam Horm. 2010;84:319-29. doi: 10.1016/B978-0-12-381517-0.00012-6.
9
Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
J Clin Endocrinol Metab. 2008 Dec;93(12):4909-16. doi: 10.1210/jc.2008-0605. Epub 2008 Sep 30.
10
GLP-1 regulates gastroduodenal motility involving cholinergic pathways.
Neurogastroenterol Motil. 2009 Jun;21(6):609-18, e21-2. doi: 10.1111/j.1365-2982.2008.01246.x. Epub 2009 Feb 6.
引用本文的文献
1
Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards.
World J Diabetes. 2024 Mar 15;15(3):326-330. doi: 10.4239/wjd.v15.i3.326.
2
Central and Peripheral Fatigue Evaluation during Physical Exercise in Athletic Horses by Means of Raman Spectroscopy.
Animals (Basel). 2023 Jul 5;13(13):2201. doi: 10.3390/ani13132201.
3
Sugars, Sweet Taste Receptors, and Brain Responses.
Nutrients. 2017 Jun 24;9(7):653. doi: 10.3390/nu9070653.
4
Relationships between gastric emptying, postprandial glycemia, and incretin hormones.
Diabetes Care. 2013 May;36(5):1396-405. doi: 10.2337/dc12-1609.
5
Peripheral neural targets in obesity.
Br J Pharmacol. 2012 Jul;166(5):1537-58. doi: 10.1111/j.1476-5381.2012.01951.x.
6
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function.
Exp Diabetes Res. 2011;2011:279530. doi: 10.1155/2011/279530. Epub 2011 Jun 22.
7
Sensing via intestinal sweet taste pathways.
Front Neurosci. 2011 Mar 3;5:23. doi: 10.3389/fnins.2011.00023. eCollection 2011.
8
The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.
Crit Care. 2009;13(3):R67. doi: 10.1186/cc7874. Epub 2009 May 13.
9
Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.
Diabetes. 2009 Jun;58(6):1342-9. doi: 10.2337/db08-0958. Epub 2009 Mar 10.
10
Upper gastrointestinal function and glycemic control in diabetes mellitus.
World J Gastroenterol. 2006 Sep 21;12(35):5611-21. doi: 10.3748/wjg.v12.i35.5611.
本文引用的文献
1
Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
Diabet Med. 2005 Aug;22(8):1016-23. doi: 10.1111/j.1464-5491.2005.01567.x.
2
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
Gut. 2006 Feb;55(2):243-51. doi: 10.1136/gut.2004.059741. Epub 2005 Jun 28.
3
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Diabetes. 2005 Jul;54(7):2212-8. doi: 10.2337/diabetes.54.7.2212.
4
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Diabetes Care. 2005 May;28(5):1092-100. doi: 10.2337/diacare.28.5.1092.
5
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Regul Pept. 2005 Jun 15;128(2):135-48. doi: 10.1016/j.regpep.2004.07.014.
6
The physiological role of GLP-1 in human: incretin, ileal brake or more?
Regul Pept. 2005 Jun 15;128(2):109-15. doi: 10.1016/j.regpep.2004.06.018.
7
Glucagon-like peptide 1(GLP-1) in biology and pathology.
Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):91-117. doi: 10.1002/dmrr.538.
8
Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes.
Diabetologia. 2004 Dec;47(12):2208-14. doi: 10.1007/s00125-004-1591-4. Epub 2004 Dec 15.
9
Postprandial hyperglycemia and diabetes complications: is it time to treat?
Diabetes. 2005 Jan;54(1):1-7. doi: 10.2337/diabetes.54.1.1.
10
Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes.
J Clin Endocrinol Metab. 2004 Jul;89(7):3431-5. doi: 10.1210/jc.2004-0334.
Zotero 插件